EGFR‐TKI exerts reasonable therapeutic effects upon EGFR‐mutation‐positive NSCLC patients10, 11, 12, 13, 14, 15, 16 but, in many cases, the development of therapeutic resistance is inevitable within several months, due to the newly acquired T790M mutation, and others.17, 18. This evidence concerns the gene EGFR and non-small cell lung carcinoma.